Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

in Patients With Acromegaly: 12-Month Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study M Sheppard,1 M Bronstein,2 P Freda,3 O Serri,4 L De Marinis,5 L Naves,6 L Rozhinskaya,7 K Hermosillo Resendiz,8 M Ruffin,9 K Asubonteng,8 A Colao10 1Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, UK; 2Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, Sao Paulo, Brazil; 3Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York, USA; 4Service of Endocrinology, Centre Hospitalier de l’Universite de Montreal, Notre-Dame Hospital, University of Montreal, Montreal, Canada; 5Section of Endocrinology, Department of Internal Medicine, Universita Cattolica del Sacro Cuore, Rome, Italy; 6Department of Endocrinology, Internal Medicine, University of Brasilia, Brasilia, Brazil; 7Department of Neuroendocrinology and Bone Diseases, Endocrinology Research Centre, Moscow, Russia; 8Clinical Development, Novartis Pharmaceuticals Corporation, Florham Park, New Jersey, USA; 9Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland; 10Dipartimento di Medicina Clinica e Chirurgia, Universita Federico II di Napoli, Naples, Italy